Effect of kisspeptin-54 on ovarian levels of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in an experimental model of ovarian hyperstimulation syndrome (OHSS)
Hülya Birinci
A * , Hafize Seda Vatansever B C and Mehmet Yüncü A
+ Author Affiliations
- Author Affiliations
A Faculty of Medicine, Department of Histology and Embryology, Gaziantep University, Gaziantep, Turkey.
B Faculty of Medicine, Department of Histology-Embryology, Manisa Celal Bayar University, Manisa, Turkey.
C DESAM Research Institute, Near East University, Mersin 10, Turkey.
Reproduction, Fertility and Development 33(16) 799-809 https://doi.org/10.1071/RD21140
Published online: 6 October 2021
© 2021 The Author(s) (or their employer(s)). Published by CSIRO Publishing
Abstract
The purpose of this study was to investigate the effect of kisspeptin-54 on ovarian morphology and vascular endothelial growth factor (VEGF), pigment epithelium-derived factor (PEDF), protein kinase A (PKA) and protein kinase C (PKC) levels in an ovarian hyperstimulation syndrome (OHSS) rat model, which is a possible complication of controlled ovarian hyperstimulation. For this purpose, immature female Sprague–Dawley rats (25 days old, 30–40 g) were randomly divided into five groups (control, sham, OHSS model, short-term kisspeptin-54 administered OHSS model and long-term kisspeptin-54 administered OHSS model). Serum LH and FSH levels were determined by enzyme-linked immunosorbent assay. Immunohistochemistry and quantitative RT-PCR were performed for VEGF, PEDF, PKA and PKC in ovaries and granulosa cells, respectively. It was observed that there was dilatation in fallopian tubes and an abnormal increase in ovarian weight and volume in the OHSS group, and these morphologies decreased with kisspeptin-54 treatment. After the administration of kisspeptin-54 in the OHSS group, VEGF, PKA and PKC levels reduced and PEDF levels increased in both mRNA and protein levels. It was determined that in the OHSS model, VEGF increased as PEDF decreased, and kisspeptin-54 reduced the effects of OHSS. It was determined that long-term kisspeptin-54 treatment was more effective than short-term administration. It is considered that kisspeptin-54 is an agent that protects ovarian reserve and oocyte maturation in women at risk of OHSS.
Keywords: cystic follicle, granulosa cell, infertility, kisspeptin-54, ovarian hyperstimulation syndrome, ovary, PEDF, VEGF.
References
Abbara, A, Jayasena, CN, Christopoulos, G, Narayanaswamy, S, Izzi-Engbeaya, C, Nijher, GM, Comninos, AN, Peters, D, Buckley, A, Ratnasabapathy, R, Prague, JK, Salim, R, Lavery, SA, Bloom, SR, Szigeti, M, Ashby, DA, Trew, GH, and Dhillo, WS (2015). Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. The Journal of Clinical Endocrinology & Metabolism 100, 3322–3331.| Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy.Crossref | GoogleScholarGoogle Scholar |
Abbara, A, Clarke, S, Islam, R, Prague, JK, Comninos, AN, Narayanaswamy, S, Papadopoulou, D, Roberts, R, Izzi-Engbeaya, C, Ratnasabapathy, R, Nesbitt, A, Vimalesvaran, S, Salim, R, Lavery, SA, Bloom, SR, Huson, L, Trew, GH, and Dhillo, WS (2017). A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a phase 2 randomized controlled trial. Human Reproduction 32, 1915–1924.
| A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a phase 2 randomized controlled trial.Crossref | GoogleScholarGoogle Scholar | 28854728PubMed |
Adam, G, İmamoğlu, T, Yaşar, F, and Erdoğan, N (2010). Kesitsel Görüntülerde Dalak Hacminin Cavalieri Yöntemiyle Saptanması Ve Formüle Dayalı Yöntemlerle Kıyaslanması. İzmir Tepecik Eğitim ve Araştırma Hastanesi Dergisi 20, 63–69.
| Kesitsel Görüntülerde Dalak Hacminin Cavalieri Yöntemiyle Saptanması Ve Formüle Dayalı Yöntemlerle Kıyaslanması.Crossref | GoogleScholarGoogle Scholar |
Algaidi, SA, Eldomiaty, MA, Elbastwisy, YM, Almasry, SM, Desouky, MK, and Elnaggar, AM (2019). Effect of voluntary running on expression of myokines in brains of rats with depression. International Journal of Immunopathology and Pharmacology 33, 2058738419833533.
| Effect of voluntary running on expression of myokines in brains of rats with depression.Crossref | GoogleScholarGoogle Scholar | 30834799PubMed |
Bar-Joseph, H, Ben-Ami, I, Ron-El, R, Shalgi, R, and Chuderland, D (2016). Pigment epithelium-derived factor regulation by human chorionic gonadotropin in granulosa cells. Reproduction 151, 179–185.
| Pigment epithelium-derived factor regulation by human chorionic gonadotropin in granulosa cells.Crossref | GoogleScholarGoogle Scholar | 26612427PubMed |
Blumenfeld, Z (2018). The ovarian hyperstimulation syndrome. Vitamins and Hormones 107, 423–451.
| The ovarian hyperstimulation syndrome.Crossref | GoogleScholarGoogle Scholar | 29544639PubMed |
Casper, RF (2015). Reducing the risk of OHSS by GnRH agonist triggering. The Journal of Clinical Endocrinology & Metabolism 100, 4396–4398.
| Reducing the risk of OHSS by GnRH agonist triggering.Crossref | GoogleScholarGoogle Scholar |
Cenksoy, C, Cenksoy, PO, Erdem, O, Sancak, B, and Gursoy, R (2014). A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model. European Journal of Obstetrics & Gynecology and Reproductive Biology 174, 86–90.
| A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.Crossref | GoogleScholarGoogle Scholar |
Chuderland, D, Ben-Ami, I, Kaplan-Kraicer, R, Grossman, H, Ron-El, R, and Shalgi, R (2013). The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice. The Journal of Clinical Endocrinology & Metabolism 98, E258–E266.
| The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice.Crossref | GoogleScholarGoogle Scholar |
Dauod L, Schenker JG (2018) Ovarian hyperstimulation syndrome (OHSS): pathogenesis and prevention. ‘Reproductive medicine for clinical practice: medical and surgical aspects’. (Eds JG Schenker, JJ Sciarra, L Mettler, AR Genazzani, MH Birkhäuser) pp. 83–92. (Springer: Berlin, Germany)
Delvigne, A, and Rozenberg, S (2002). Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update 8, 559–577.
| Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.Crossref | GoogleScholarGoogle Scholar | 12498425PubMed |
Depalo, R, Jayakrishan, K, Garruti, G, Totaro, I, Panzarino, M, Giorgino, F, and Selvaggi, LE (2012). GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reproductive Biology and Endocrinology 10, 26.
| GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET).Crossref | GoogleScholarGoogle Scholar | 22500852PubMed |
Fernandois, D, Na, E, Cuevas, F, Cruz, G, Lara, H, and Paredes, AH (2016). Kisspeptin is involved in ovarian follicular development during aging in rats. Journal of Endocrinology 228, 161–170.
| Kisspeptin is involved in ovarian follicular development during aging in rats.Crossref | GoogleScholarGoogle Scholar |
Howard CV, Reed MG (1998) ‘Unbiased sterology: three-dimensional measurement in microscopy’. pp. 39–68. (BIOS Scientific: Oxford, UK)
Hu, K-L, Zhao, H, Chang, H-M, Yu, Y, and Qiao, J (2018). Kisspeptin/kisspeptin receptor system in the ovary. Frontiers in Endocrinology 8, 365.
| Kisspeptin/kisspeptin receptor system in the ovary.Crossref | GoogleScholarGoogle Scholar | 29354093PubMed |
Humaidan, P, Nelson, SM, Devroey, P, Coddington, CC, Schwartz, LB, Gordon, K, Frattarelli, JL, Tarlatzis, BC, Fatemi, HM, Lutjen, P, and Stegmann, BJ (2016). Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Human Reproduction 31, 1997–2004.
| Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials.Crossref | GoogleScholarGoogle Scholar | 27343272PubMed |
Hunjan, T, and Abbara, A (2019). Clinical translational studies of Kisspeptin and Neurokinin B. Seminars in Reproductive Medicine 37, 119–124.
| Clinical translational studies of Kisspeptin and Neurokinin B.Crossref | GoogleScholarGoogle Scholar | 31869839PubMed |
Kafa, İM, and Eyigör, Ö (2011). Kisspeptinler ve kisspeptin nöronları: Üreme sistemi üzerine etkileri ve hipotalamik yerleşimleri. Uludağ Üniversitesi Tıp Fakültesi Dergisi 37, 53–60.
Kitajima, Y, Endo, T, Manase, K, Nishikawa, A, Shibuya, M, and Kudo, R (2004). Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats. Fertility and Sterility 81, 842–849.
| Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats.Crossref | GoogleScholarGoogle Scholar | 15019818PubMed |
Kummer, NE, Weitzman, VN, Benadiva, CA, Schmidt, DW, Engmann, LL, and Nulsen, JC (2011). In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle. Fertility and Sterility 95, 2592–2594.
| In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle.Crossref | GoogleScholarGoogle Scholar | 21292260PubMed |
Luke, B, Brown, MB, Morbeck, DE, Hudson, SB, Coddington, CC, and Stern, JE (2010). Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome. Fertility and Sterility 94, 1399–1404.
| Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome.Crossref | GoogleScholarGoogle Scholar | 19591989PubMed |
Matsui, H, Takatsu, Y, Kumano, S, Matsumoto, H, and Ohtaki, T (2004). Peripheral administration of metastin induces marked gonadotropin release and ovulation in the rat. Biochemical and Biophysical Research Communications 320, 383–388.
| Peripheral administration of metastin induces marked gonadotropin release and ovulation in the rat.Crossref | GoogleScholarGoogle Scholar | 15219839PubMed |
Miller, I, Chuderland, D, Grossman, H, Ron-El, R, Ben-Ami, I, and Shalgi, R (2016). The dual role of PEDF in the pathogenesis of OHSS: negating both angiogenic and inflammatory pathways. The Journal of Clinical Endocrinology & Metabolism 101, 4699–4709.
| The dual role of PEDF in the pathogenesis of OHSS: negating both angiogenic and inflammatory pathways.Crossref | GoogleScholarGoogle Scholar |
Mourad, S, Brown, J, and Farquhar, C (2017). Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 1, CD012103.
| Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.Crossref | GoogleScholarGoogle Scholar |
Nastri, CO, Ferriani, RA, Rocha, IA, and Martins, WP (2010). Ovarian hyperstimulation syndrome: pathophysiology and prevention. Journal of Assisted Reproduction and Genetics 27, 121–128.
| Ovarian hyperstimulation syndrome: pathophysiology and prevention.Crossref | GoogleScholarGoogle Scholar | 20140640PubMed |
Owens, LA, Abbara, A, Lerner, A, O’floinn, S, Christopoulos, G, Khanjani, S, Islam, R, Hardy, K, Hanyaloglu, AC, Lavery, SA, Dhillo, WS, and Franks, S (2018). The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function. Human Reproduction 33, 292–302.
| The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function.Crossref | GoogleScholarGoogle Scholar | 29206944PubMed |
Soares, SR, Gómez, R, Simón, C, García-Velasco, JA, and Pellicer, A (2008). Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Human Reproduction Update 14, 321–333.
| Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.Crossref | GoogleScholarGoogle Scholar | 18385260PubMed |
van den Driesche, S, Myers, M, Gay, E, Thong, KJ, and Duncan, WC (2008). HCG up-regulates hypoxia inducible factor-1 alpha in luteinized granulosa cells: implications for the hormonal regulation of vascular endothelial growth factor A in the human corpus luteum. Molecular Human Reproduction 14, 455–464.
| HCG up-regulates hypoxia inducible factor-1 alpha in luteinized granulosa cells: implications for the hormonal regulation of vascular endothelial growth factor A in the human corpus luteum.Crossref | GoogleScholarGoogle Scholar | 18591213PubMed |
Wang, TH, Horng, SG, Chang, CL, Wu, HM, Tsai, YJ, Wang, HS, and Soong, YK (2002). Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. The Journal of Clinical Endocrinology & Metabolism 87, 3300–3308.
| Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.Crossref | GoogleScholarGoogle Scholar |
Zhai, J, Liu, J, Zhao, S, Zhao, H, Chen, ZJ, Du, Y, and Li, W (2017). Kisspeptin-10 inhibits OHSS by suppressing VEGF secretion. Reproduction 154, 355–362.
| Kisspeptin-10 inhibits OHSS by suppressing VEGF secretion.Crossref | GoogleScholarGoogle Scholar | 28676533PubMed |
